☆ 4.6 Letter

Idiopathic pulmonary fibrosis: is all-cause mortality a practical and realistic end-point for clinical trials?

THORAX (2013)

Journal

THORAX

Volume 68, Issue 5, Pages 491-492

Publisher

BMJ PUBLISHING GROUP

DOI: 10.1136/thoraxjnl-2012-203114

Keywords

-

Categories

Respiratory System

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Respiratory System

Cutoff Points for Step Count to Predict 1-year All-Cause Mortality in Patients with Idiopathic Pulmonary Fibrosis

Kazuya Shingai, Toshiaki Matsuda, Yasuhiro Kondoh, Tomoki Kimura, Kensuke Kataoka, Toshiki Yokoyama, Yasuhiko Yamano, Tomoya Ogawa, Fumiko Watanabe, Jun Hirasawa, Ryo Kozu

Summary: This study investigated the prognostic significance of physical activity assessed by step count in patients with idiopathic pulmonary fibrosis. Results showed that a daily step count exceeding 3,473 steps at the time of diagnosis significantly lowered mortality among patients. These findings emphasize the importance of assessing physical activity in this patient population.

RESPIRATION (2021)

Add to Collection

Article Critical Care Medicine

Managing Cough in Idiopathic Pulmonary Fibrosis

Yosafe Wakwaya, Deepa Ramdurai, Jeffrey J. Swigris

Summary: Chronic cough in patients with IPF may involve multiple mechanisms, including comorbid conditions and IPF itself. Diagnostic and management approaches need to be multi-faceted, but may lack robust data support.

CHEST (2021)

Add to Collection

Article Respiratory System

Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receivingantifibrotictherapy

Yuzo Suzuki, Yuya Aono, Masato Kono, Hirotsugu Hasegawa, Koushi Yokomura, Hyogo Naoi, Hironao Hozumi, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Yutaro Nakamura, Naoki Inui, Hidenori Nakamura, Takafumi Suda

Summary: Patients with IPF undergoing AFT treatment showed skeletal muscle loss without obvious weight loss. Chronic respiratory failure was the most common cause of mortality, and skeletal muscle wasting had prognostic significance, emphasizing the importance of preventing sarcopenia and preserving lung function in managing these patients.

RESPIROLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Dissecting the Role of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis: Cause or Solution

Anna Valeria Samarelli, Roberto Tonelli, Irene Heijink, Aina Martin Medina, Alessandro Marchioni, Giulia Bruzzi, Ivana Castaniere, Dario Andrisani, Filippo Gozzi, Linda Manicardi, Antonio Moretti, Stefania Cerri, Riccardo Fantini, Luca Tabbi, Chiara Nani, Ilenia Mastrolia, Daniel J. Weiss, Massimo Dominici, Enrico Clini

Summary: Idiopathic pulmonary fibrosis (IPF) is a aggressive form of idiopathic interstitial pneumonias characterized by chronic and progressive fibrosis, resulting in lung functional decline, respiratory failure, and high mortality. The role of endogenous MSCs in the lungs and the potential therapeutic role of administered MSCs from other sources for IPF are still under debate.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Review Biology

Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis

Lorraine Thong, Enda James McElduff, Michael Thomas Henry

Summary: This review article summarizes the existing and novel pharmacotherapies for the treatment of idiopathic pulmonary fibrosis (IPF), focusing on the current knowledge on the pathophysiology of the disease, mechanism of action of the drugs, and clinical trials.

LIFE-BASEL (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Clinicopathological Outlines of Post-COVID-19 Pulmonary Fibrosis Compared with Idiopathic Pulmonary Fibrosis

Roxana-Elena Cirjaliu, Mariana Deacu, Ioana Gherghisan, Angela Stefania Marghescu, Manuela Enciu, Gabriela Izabela Baltatescu, Antonela Anca Nicolau, Doina-Ecaterina Tofolean, Oana Cristina Arghir, Ariadna-Petronela Fildan

Summary: This review provides a comprehensive analysis of the risk factors, clinical, radiologic, and histological features of both post-COVID-19 pulmonary fibrosis (PCPF) and idiopathic pulmonary fibrosis (IPF). It highlights the similarities and differences between these two diseases by gathering relevant articles published in English up until October 2022 using multiple databases. This review aims to assist clinicians, pathologists, and researchers in making accurate diagnoses and selecting patients for anti-fibrotic therapies and future therapeutic perspectives.

BIOMEDICINES (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

End-to-end domain knowledge-assisted automatic diagnosis of idiopathic pulmonary fibrosis (IPF) using computed tomography (CT)

Wenxi Yu, Hua Zhou, Jonathan G. Goldin, Weng Kee Wong, Grace Hyun J. Kim

Summary: This study utilizes an optimality design criterion and population-level domain knowledge to propose a new statistical method for constructing an IPF diagnostic model, focusing on patient-level IPF diagnosis.

MEDICAL PHYSICS (2021)

Add to Collection

Review Medicine, General & Internal

Idiopathic Pulmonary Fibrosis and Telomeres

Alba Mulet, Jaime Signes-Costa

Summary: Idiopathic pulmonary fibrosis is a lung disease with unknown causes, which has a poor prognosis. Telomeric shortening may play an important role in its pathogenesis, but mutations in telomere-related genes are not always present. Telomere shortening can serve as a biomarker for disease prognosis independently of other clinical factors.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Statins: cause of fibrosis or the opposite? Effect of cardiovascular drugs in idiopathic pulmonary fibrosis

Eline M. Lambert, Wim A. Wuyts, Jonas Yserbyt, Laurens J. De Sadeleer

Summary: This study found that statin users exhibited significantly slower progression of IPF, while the effects of antiaggregant therapy were inconclusive. Anticoagulant use showed a trend towards worsened DLCO decline, and metformin therapy did not affect IPF progression or survival.

RESPIRATORY MEDICINE (2021)

Add to Collection

Review Pharmacology & Pharmacy

Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis

Xudan Yang, Zhihao Xu, Songhua Hu, Juan Shen

Summary: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease without a known cause. Current approved drugs for IPF, such as Pirfenidone and Nintedanib, can slow down the decline in lung function and reduce the risk of acute worsening. However, they cannot alleviate symptoms or improve overall survival. The development of new, safe, and effective drugs is necessary. Previous studies have shown that cyclic nucleotides and phosphodiesterase inhibitors may be potential targets for treating pulmonary fibrosis. This paper reviews the progress in research on PDE inhibitors and provides insights for the development of anti-pulmonary fibrosis drugs.

FRONTIERS IN PHARMACOLOGY (2023)

Add to Collection

Article Respiratory System

End-of-life care for idiopathic pulmonary fibrosis patients with acute exacerbation

Norimichi Akiyama, Tomoyuki Fujisawa, Tatsuya Morita, Takafumi Koyauchi, Yoshinobu Matsuda, Masanori Mori, Mitsunori Miyashita, Ryo Tachikawa, Keisuke Tomii, Hiromi Tomioka, Satoshi Hagimoto, Yasuhiro Kondoh, Yoshikazu Inoue, Takafumi Suda

Summary: This study investigated the palliative care received by patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF), focusing on opioid use for dyspnea and end-of-life discussions. The results showed that opioids are mainly administered when recovery is deemed impossible and end-of-life discussions are rarely held before the onset of AE.

RESPIRATORY RESEARCH (2022)

Add to Collection

Article Biochemistry & Molecular Biology

B4GALT1 as a New Biomarker of Idiopathic Pulmonary Fibrosis

Claudia De Vitis, Michela D'Ascanio, Andrea Sacconi, Dario Pizzirusso, Valentina Salvati, Massimiliano Mancini, Giorgia Scafetta, Roberto Cirombella, Francesca Ascenzi, Sara Bruschini, Antonella Esposito, Silvia Castelli, Claudia Salvucci, Leonardo Teodonio, Bruno Sposato, Angela Catizone, Arianna Di Napoli, Andrea Vecchione, Gennaro Ciliberto, Salvatore Sciacchitano, Alberto Ricci, Rita Mancini

Summary: The study revealed that the B4GALT1 gene is overexpressed in IPF patients and human cell cultures, indicating it could serve as a potential novel marker for this disease.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Pharmacology & Pharmacy

Small airway dysfunction in idiopathic pulmonary fibrosis

Chengsheng Yin, Huikang Xie, Xian He, Yuan Zhang, Aihong Zhang, Huiping Li

Summary: This study aimed to investigate the occurrence of small airway dysfunction (SAD) comorbidity in idiopathic pulmonary fibrosis (IPF) and its impact on survival. The study found that 34.57% of IPF patients were diagnosed with SAD, and comorbid SAD was an independent risk factor for mortality in IPF patients.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Review Medicine, General & Internal

Precision medicine advances in idiopathic pulmonary fibrosis

Theodoros Karampitsakos, Brenda M. Juan-Guardela, Argyris Tzouvelekis, Jose D. Herazo-Maya

Summary: Idiopathic pulmonary fibrosis (IPF) is a highly heterogeneous and lethal chronic lung disease. Precision medicine approaches have not been effectively implemented in IPF clinical practice, despite the existence of numerous diagnostic, prognostic, and theragnostic biomarker candidates.

EBIOMEDICINE (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Environmental Causes of Idiopathic Pulmonary Fibrosis

Sheiphali Gandhi, Roberto Tonelli, Margaret Murray, Anna Valeria Samarelli, Paolo Spagnolo

Summary: Idiopathic pulmonary fibrosis (IPF) is a common and severe disease that primarily affects middle-aged and elderly males. In addition to aging, occupational and environmental exposures, as well as lifestyle factors such as smoking and diet, have been associated with an increased risk of IPF. Trigger factors may also lead to acute exacerbations and poor prognosis.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Letter Respiratory System

Moderate resting hypoxaemia in fibrotic interstitial lung disease

Yet H. Khor, Amelia Harrison, Julien Robinson, Nicole S. L. Goh, Ian Glaspole, Christine F. McDonald

EUROPEAN RESPIRATORY JOURNAL (2021)

Add to Collection

Article Respiratory System

Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand*

Adelle S. Jee, Robert Sheehy, Peter Hopkins, Tamera J. Corte, Christopher Grainge, Lauren K. Troy, Karen Symons, Lissa M. Spencer, Paul N. Reynolds, Sally Chapman, Sally de Boer, Taryn Reddy, Anne E. Holland, Daniel C. Chambers, Ian N. Glaspole, Helen E. Jo, Jane F. Bleasel, Jeremy P. Wrobel, Leona Dowman, Matthew J. S. Parker, Margaret L. Wilsher, Nicole S. L. Goh, Yuben Moodley, Gregory J. Keir

Summary: Pulmonary complications in CTD commonly involve various parts of the lungs and ILD can vary in severity, making accurate diagnosis and careful treatment decisions important. Management of CTD-ILD can be challenging due to limited data and the need for individualized approaches.

RESPIROLOGY (2021)

Add to Collection

Review Allergy

Hypersensitivity pneumonitis: Current concepts in pathogenesis, diagnosis, and treatment

Hayley Barnes, Lauren Troy, Cathryn T. Lee, Anne Sperling, Mary Strek, Ian Glaspole

Summary: Hypersensitivity pneumonitis is an immune-mediated interstitial lung disease that requires exposure history and multiple tests for diagnosis, including HRCT, serum IgG testing, bronchoalveolar lavage, and lung biopsy, with treatment involving avoidance of exposure, immunosuppression, and anti-fibrotic therapy in select cases.

ALLERGY (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Self-management for pulmonary fibrosis: Insights from people living with the disease and healthcare professionals

Joanna Y. T. Lee, Gabriella Tikellis, Ian Glaspole, Yet H. Khor, Karen Symons, Anne E. Holland

Summary: This study explores the needs and expectations of PF self-management from the perspectives of patients and healthcare professionals, identifying individualized strategies, supports, and reliable information as key components for effective self-management. Exercise, nutrition, maintaining healthy mind, and social support are reported as common self-management components.

PATIENT EDUCATION AND COUNSELING (2022)

Add to Collection

Article Respiratory System

Physical activity decline is disproportionate to decline in pulmonary physiology in IPF

Jyotika D. Prasad, Eldho Paul, Anne E. Holland, Ian N. Glaspole, Glen P. Westall

Summary: In patients with IPF, there is a significant decline in DPA over 12 months, which is disproportionate to the decline in pulmonary physiology. However, changes in DPA are weakly to moderately correlated with FVC % predicted and 6MWD, but not associated with long-term survival.

RESPIROLOGY (2021)

Add to Collection

Article Physiology

Coagulation factor-XII induces interleukin-6 by primary lung fibroblasts: a role in idiopathic pulmonary fibrosis?

Jade Jaffar, Laura McMillan, Nick Wilson, Con Panousis, Charles Hardy, Hyun-Jung Cho, Karen Symons, Ian Glaspole, Glen Westall, Mae Wong

Summary: This study found that plasma levels of factor XII (FXII) were not higher in patients with idiopathic pulmonary fibrosis (IPF) compared to healthy donors, but tissue FXII levels were elevated in IPF. FXII can induce IL-6 production and enhance migration of fibroblasts, contributing to chronic inflammation and fibrotic disease progression in IPF.

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2022)

Add to Collection

Article Respiratory System

Biomarker signatures for progressive idiopathic pulmonary fibrosis

Britt Clynick, Tamera J. Corte, Helen E. Jo, Iain Stewart, Ian N. Glaspole, Christopher Grainge, Toby M. Maher, Vidya Navaratnam, Richard Hubbard, Peter M. A. Hopkins, Paul N. Reynolds, Sally Chapman, Christopher Zappala, Gregory J. Keir, Wendy A. Cooper, Annabelle M. Mahar, Samantha Ellis, Nicole S. Goh, Emma De Jong, Lilian Cha, Dino B. A. Tan, Lucy Leigh, Christopher Oldmeadow, E. Haydn Walters, R. Gisli Jenkins, Yuben Moodley

Summary: This study evaluated the prognostic role of serum biomarkers in patients with idiopathic pulmonary fibrosis (IPF) in three independent cohorts. Circulatory biomarkers were found to provide valuable clinical assistance in predicting disease progression and survival risk in IPF patients.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection

Editorial Material Respiratory System

Progressive fibrosing hypersensitivity pneumonitis: Why wait?

Hayley Barnes, Ian N. Glaspole

RESPIROLOGY (2022)

Add to Collection

Article Respiratory System

Barriers and facilitators to best care for idiopathic pulmonary fibrosis in Australia

Gabriella Tikellis, Tamera J. Corte, Alan K. Y. Teoh, Ian N. Glaspole, Sacha Macansh, Anne E. Holland

Summary: The clinical management of IPF in Australia generally aligns with best practice guidance, but there may be some inequity of access to specialist services, particularly in regional areas, that should be addressed to ensure optimal care for all.

RESPIROLOGY (2022)

Add to Collection

Article Respiratory System

Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in Australia

Ingrid A. Cox, Petr Otahal, Barbara Graaff, Tamera J. Corte, Yuben Moodley, Chris Zappala, Ian Glaspole, Peter Hopkins, Sacha Macansh, E. Haydn Walters, Andrew J. Palmer

Summary: This study utilized the MIAMOD method and software to estimate the mortality, incidence, and prevalence of IPF in Australia, with results showing an increase in these rates over the study period but a projected decrease in the future. The majority of IPF cases and deaths were found in individuals over 70 years old, with higher rates observed in males compared to females.

RESPIROLOGY (2022)

Add to Collection

Article Respiratory System

High intensity interval training versus moderate intensity continuous training for people with interstitial lung disease: protocol for a randomised controlled trial

Leona M. Dowman, Anthony K. May, Catherine J. Hill, Janet Bondarenko, Lissa Spencer, Norman R. Morris, Jennifer A. Alison, James Walsh, Nicole S. L. Goh, Tamera Corte, Ian Glaspole, Daniel C. Chambers, Christine F. McDonald, Anne E. Holland

Summary: This study aims to compare the clinical benefits of high intensity interval exercise training versus standard pulmonary rehabilitation method in fibrotic interstitial lung disease patients. The primary outcome is endurance time, with secondary outcomes including functional capacity, health-related quality of life, breathlessness, fatigue, anxiety, physical activity level, skeletal muscle changes, and completion of pulmonary rehabilitation programs.

BMC PULMONARY MEDICINE (2021)

Add to Collection

Article Respiratory System

TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis

John A. Mackintosh, Maria Pietsch, Viviana Lutzky, Debra Enever, Sandra Bancroft, Simon H. Apte, Maxine Tan, Stephanie T. Yerkovich, Joanne L. Dickinson, Hilda A. Pickett, Hiran Selvadurai, Christopher Grainge, Nicole S. Goh, Peter Hopkins, Ian Glaspole, Paul N. Reynolds, Jeremy Wrobel, Adam Jaffe, Tamera J. Corte, Daniel C. Chambers

Summary: Recent discoveries have found shortened telomeres and related mutations in people with pulmonary fibrosis. Androgens, including danazol, are believed to be effective in lengthening telomeres in blood cells. This study aims to assess the safety and efficacy of danazol in both adults and children with PF associated with telomere shortening.

BMJ OPEN RESPIRATORY RESEARCH (2021)

Add to Collection

Article Medicine, General & Internal

The Perceptions of Telehealth Physiotherapy for People with Bronchiectasis during a Global Pandemic-A Qualitative Study

Annemarie L. Lee, Louise Tilley, Susy Baenziger, Ryan Hoy, Ian Glaspole

Summary: This study conducted interviews with bronchiectasis patients who received telehealth physiotherapy, and identified four themes. The findings provide valuable insights for future modifications of telehealth physiotherapy models.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Respiratory System

Essential Features of an Interstitial Lung Disease Multidisciplinary Meeting An International Delphi Survey

Alan K. Y. Teoh, Anne E. Holland, Julie Morisset, Kevin R. Flaherty, Athol U. Wells, Simon L. F. Walsh, Ian Glaspole, Wim A. Wuyts, Tamera J. Corte

Summary: This study achieved consensus among international ILD experts on the essential and desirable features of an ILD MDM through the use of a Delphi methodology. The findings provide important data for potential collaborative research on the standardization of ILD MDMs in the future.

ANNALS OF THE AMERICAN THORACIC SOCIETY (2022)

Add to Collection

Article Respiratory System

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities

Ian Glaspole, Francesco Bonella, Elena Bargagli, Marilyn K. Glassberg, Fabian Caro, Wibke Stansen, Manuel Quaresma, Leticia Orsatti, Elisabeth Bendstrup

Summary: The study evaluated the efficacy and safety of nintedanib in treating IPF, finding that it can reduce FVC decline rate consistently across different age and comorbidity burden subgroups. Proactive management of adverse events is important to help patients remain on therapy.

RESPIRATORY RESEARCH (2021)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.